Annual Meeting
Every fall, the CPCI holds an annual meeting attended by all who contribute to the Consortium, the External Advisory Board, and the NIH-NCATS Program Director. Slides from past meetings available here.
Meetings
Consortium for Pediatric Cellular Immunotherapy
Symposia
Occasionally the CPCI hosts a deeper discussion on a topic of special interest to the field. Slides from past symposia available here.
Quarterly Scientific Talk Series
One of the goals of the CPCI is to provide opportunities for junior faculty to present their work. Here is a list of all past presenters and their presentations:
| Presenter | Topic | Site |
|---|---|---|
| Katie Albert, MD | Patterns of engraftment and toxicity on the STRIvE (EGFR and B7H3-directed) CAR T cell clinical trials | Seattle Children’s |
| Colleen Annesley, MD | Preliminary Results of CD19-expressing T cell antigen presenting cells infused episodically following CD19 CAR T cell therapy in B-ALL | Seattle Children's |
| Sagar Bapat, MD, PhD | Beyond killing: Developing a T cell therapy that modifies and enhances tissue function | University of California San Francisco |
| Elizabeth Crouch, MD, PhD | Development of the human neurovascular unit: vulnerabilities and opportunities | University of California, San Francisco |
| Russell Cruz, MD, PhD | Cell therapies for brain tumors | Children's National |
| Hema Dave, MD, MPH | Assessing the immune landscape in Hodgkin’s Lymphoma: From bench to bedside and beyond | Children's National |
| Julaine Gust, MD, PhD | CAR T neurotoxicity: we’re not done yet | Seattle Children's |
| Bindu Hegde, PhD | T cell-based therapy targeting H3.3K27M neoantigen in pediatric patients with diffuse midline glioma | University of California, San Francisco |
| Amy Hont, MD | Presentation of TAA-T cell data | Children's National |
| Adam Johnson, PhD | Optimal CD22 chimeric antigen receptor activity hinges on spacer type and configuration | Seattle Children's |
| Hannah Kinoshita, MD | Outcomes of post-transplant virus-specific T cell therapy in patients with sickle cell disease | Children’s National |
| Hannah Kinoshita, MD | TAA-T cell therapy for patients with acute leukemia after BMT | Children's National |
| Eric Kohler, MD, PhD | Restoration of LAT signaling enhances antigen-sensitivity, persistence and potency of CAR T cells against acute leukemias | Children’s Hospital Colorado |
| Eric Kohler, MD, PhD | Understanding the chimeric antigen receptor signal and its impact on CAR T cell function and efficacy | Children's Hospital Colorado |
| Jessica Lake, MD, MPH | Driving CARTs to sarcoma | University of Colorado Anschutz Medical Center |
| Mike Leibowitz, MD, PhD | Increasing epitope spreading to improve CAR T cell therapy for solid tumors | Children’s Hospital Colorado |
| Siddhartha Mitra, PhD | Macrophage immunotherapy for malignant brain tumors | Children's Hospital Colorado |
| Babak Moghimi, MD | Developing SynNotch gated CAR-T cells to target a combination of CD123 and CD33 in AML | Children's Hospital Los Angeles |
| David Nguyen, MD, PhD | Developing applications of CRISPR gene editing for diagnosing and treating primary immunodeficiency | University of California, San Francisco |
| Chintan Parekh, MD | BCL11B activation as an approach for enhancing the efficacy of immunotherapy | Children's Hospital Los Angeles |
| Sarah Richman, MD, PhD | Regulation of chimeric antigen receptor expression via ligand-induced degradation | Children's Hospital Los Angeles |
| Brian Shy, MD, PhD | Gene-corrected Treg therapy for treatment of IL2RA deficiency | University of California San Francisco |
| Keri Toner, MD | Off the shelf EBV specific T cells for pediatric PTLD: An update on COG ANHL1522 | Children’s National |
| Nicholas Vitanza, MD | Initial experience of the BrainChild trials: repeated locoregional HER2, EGFR, and B7-H3 CAR T cells for children with CNS tumors | Seattle Children's |
| Peter Yingxiao Wang, PhD | Ultrasound controllable genetics and CAR T for solid tumor therapy | University of Southern California |
| Jianming Xie, PhD | Engineering natural killer cells to target hematologic malignancies with HLA-DR loss | University of Southern California |